Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 6Melanoma 6Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Neoplasm Metastasis 4Multiple Myeloma 4Mouth Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Neoplasms 3Head and Neck Neoplasms 3Colonic Neoplasms 3Uterine Cervical Dysplasia 2Skin Neoplasms 2Sarcoma, Kaposi 2Sarcoma 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Inflammatory Breast Neoplasms 2HIV Infections 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Unspecified Adult Solid Tumor, Protocol Specific 1Turcot syndrome 1Thrombocytosis 1

Interventions

Nivolumab 2tislelizumab 1avelumab 1Taxes 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Ipilimumab 1Fluorouracil 1Carboplatin 1Capecitabine 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Turcot syndrome × Biopsy × Clear all
NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡